Ann: Positive final results from IHL-42X phase 2 trial, page-7

Looks like I will be sleeping well on this news over the weekend.

and might not be first in line for treatment but I will be darn close!

Medium and High also fell under the limits of 1-2 ng/mL - brilliant results

And this :

The reduction in AHI observed during IHL-42X treatment periods means that when treated with Incannex’s proprietary drug, subject’s breathing was interrupted less frequently during sleep. This supports Incannex’s hypothesis that IHL-42X is an effective treatment for OSA. The observation that
low dose IHL-42X was the most effective at reducing AHI is encouraging for the development of IHL42X as a pharmaceutical as a lower dose will reduce risk of side effects and the cost of goods.

Furthermore, greater reduction in AHI with low dose IHL-42X compared to dronabinol and acetazolamide at equivalent doses supports Incannex’s hypothesis that the two drugs are acting synergistically to reduce AHI and provides confidence that IHL-42X will meet the FDA’s combination
rule where both APIs must contribute to the therapeutic effect of a fixed dose combination product.